Ingelvac PRRS® MLV, a leading modified-live PRRS vaccine, has been trusted for over 20 years to protect the swine industry against respiratory and reproductive symptoms of PRRSv.
Ingelvac PRRS® MLV is a modified-live PRRS vaccine that is proven safe in pigs as well as gilts and sows at any stage of production in PRRS positive herds. It provides cross protection against heterologous challenge; (including Lelystad virus) and has shown to significantly reduce reproductive failure and respiratory disease due to PRRS virus. 1,2
- Trusted and field proven
- Cost effective
- Unique in its ability to be used in pigs (3 weeks or older), gilts, and sows at ANY stage of production
- Available in three convenient sizes (10, 50, and 250 dose)
Porcine Reproductive and Respiratory Syndrome (PRRS) is a $664 million dollar problem.3 It has a devastating impact on pig performance, overall production and profits. Unlike many other swine diseases, the unique, single-strand RNA structure of the PRRS virus has made it a challenge for a generation of pork producers.
For over 20 years, Boehringer Ingelheim Vetmedica Inc. has been helping the industry combat PRRS. With Ingelvac PRRS® vaccines, technical expertise, collaborative research and diagnostic advancements, we are working with veterinarians and producers to win the battles against this challenging disease.
Top Reasons to Use Ingelvac PRRS® MLV
- Demostrated cross protection
Ingelvac PRRS® MLV has demonstrated cross-protection against the most current strains of PRRSv and continues to be evaluated in order to provide you with the most up-to-date information.4
- Most extensive PRRS vaccine line
Boehringer Ingelheim Vetmedica, Inc. offers the widest range of PRRS vaccines available, both single antigen and in combination, in a variety of dosage sizes to best meet the needs of your protocol and operation.
- Use at any stage of production
Ingelvac PRRS® is the leader in whole herd protection. Proven safe and efficacious in pigs, gilts, and sows.5
- Field research on viral shedding
In a study, Ingelvac PRRS® MLV–vaccinated pigs had a significant reduction in aerosol shedding of wild-type PRRSv compared to non-vaccinated pigs.6
- Controlling PRRS helps achieve healthy pig performance
Pigs challenged with PRRSv have worse average daily gains and higher mortality rates with estimated profit loss of $4.32 per pig.7 Choose with confidence — Ingelvac PRRS® MLV aids in the prevention of respiratory disease associated with PRRSv.
Ingelvac PRRS® MLV mixing guide
Directions and dosage: Rehydrate the vaccine by adding a portion of the contents of the accompanying diluent to the vaccine vial. Shake well and transfer the reconstituted suspension back into the diluent bottle, mix with the remaining diluent to complete to a total volume of 500 mL. Shake well and use immediately. See insert for complete information.
Features
- Safe in pigs, gilts and sows at any stage of production.
- Aids in the prevention of respiratory disease and aids in the reduction of reproductive disease caused by PRRS virus.
- Proven cross protection against heterologous challenge; (including Lelystad virus).
- Easy to use, cost effective and field proven against respiratory and reproductive forms of PRRS Virus.
- Convenience of 10, 50 and 250 dose presentations.
Benefits
- Long-lasting immunity. Duration of immunity is at least 4 months.
- Whole herd or population based PRRS control program advantages.
- Significantly reduces reproductive failure due to PRRS virus.
- Gilt stabilization/acclimatization program advantages.
- Whole herd or population based PRRS control programs.
- Replacement gilt immunizationand preparation.
- Reproductive maintenance vaccination program in sows.
- Administration in growing pigs to aid in prevention of respiratory disease
For Swine use only. Do not vaccinate boars
Anaphylactoid reactions may occur, antidote: administer epinephrine
Withdraw period of 21 days
Ingelvac PRRS® MLV is not recommended for use in PRRS negative (naïve) herds
For complete safety information see the Material Safety Data Sheet (MSDS)
Ingelvac PRRS® MLV utilizes the same intramuscular (IM) dose size (2 mL) for pigs, adult breeding-age or pregnant females.
Pigs, gilts and sows: Ingelvac PRRS® MLV is recommended for use in healthy susceptible swine in PRRS virus-positive herds according to label direction. Using aseptic technique, administer a single 2 mL dose intramuscularly (IM) for the respiratory and reproductive form of the disease. The duration of immunity is throughout the finishing or gestation period, or at least 4 months post vaccination.
The vaccine can be used at any stage of production. Revaccination of the whole herd can occur every 3-4 months or as directed by your veterinarian.
DO NOT VACCINATE BOARS.
Directions and dosage
Rehydrate the vaccine by adding a portion of the contents of the accompanying diluent to the vaccine vial. Shake well and transfer the reconstituted suspension back into the diluent bottle, mix with the remaining diluent to complete to a total volume of 500 mL. Shake well and use immediately. See insert for complete information.
1. Data on file, Study Report No. ID-DLO 109 1994 09.
2. Data on file, Study Report No. 623-850-95P-031
3. Holtkamp, D. 2012. PRRS virus control or elimination-How to assess which is right for individual breeding herds. 53rd Annual George A. Young Swine Health and Management Conference. P5-p15
4. Patterson A, Victoria J, Jordan D, et al. Modified-live PRRSv vaccination is efficacious following challenge with eight genetically diverse PRRSv isolates. Leman Conference, 2013.
5. Do not use in breeding-age boars.
6. Dee S, Nerem J, Wetzell T, et al. 2014. Reduction of wild-type PRRS virus shedding in aerosol of growing pigs by modified-live virus vaccination at weaning.Proceedings – American Association of Swine Veterinarians Annual Meeting, 461–462.
7. Holtkcamp D, et al. 2013. Assessment of the economic impact of porcine reproductive and respiratory syndrome virus on United States pork producers. J Swine Health Prod 21:72–84.Ingelvac PRRS is a registered trademark of Boehringer Ingelheim Vetmedica, GmbH, Ingelheim, Germany. ©2015 Boehringer Ingelheim Vetmedica, Inc. BIVI/PRS/151018
